News

BlogsPosts
Event
2019 EBD Biotech Showcase
RepliCel is excited to have been chosen to present at next year's EBD Biotech Showcase
BlogsPosts
Press Release
RepliCel Life Sciences Appoints Head of Clinical and Regulatory Affairs
Appointment of Dr. Goessens-Rueck strengthens management team and fulfils commitment to promote female leadership in
BlogsPosts
Press Release
RepliCel Announces Federal Grant Funding for Collaboration with the University of Victoria, Canada
The National Sciences and Engineering Research Council of Canada has funded a University of Victoria
BlogsPosts
As Seen In
Groundbreaking Biotech Company Takes Major Step Forward with Deal with Chinese Partner
Canada-based biotech company signs major deal with Chinese partner to advance
BlogsPosts
Press Release
RepliCel Life Sciences Appoints New Chief Financial Officer
VANCOUVER, Oct. 17, 2018 /CNW/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV:
BlogsPosts
Press Release
RepliCel CEO Provides Updated Outlook
Partnership and Investment Fuel Plans for Upcoming Advancements VANCOUVER, Oct. 15, 2018
BlogsPosts
Press Release
RepliCel Life Sciences Completes Financing with YOFOTO (China) Health
  YOFOTO (China) Health and RepliCel Life Sciences finalize investment and commence collaboration activity in Greater China
BlogsPosts
Press Release
RepliCel Life Sciences and YOFOTO (China) Health Obtain All Approvals Needed to Complete Investment
YOFOTO (China) Health and RepliCel Life Sciences now cleared to close
BlogsPosts
As Seen In
Partnership Greenlighted for Canadian Biotech and Chinese Health Products Firm
RepliCel Life Sciences Inc. (RP:TSX.V; REPCF:OTCQB) and YOFOTO Health Industry Co.
BlogsPosts
As Seen In
Canadian Technology and Innovation: making strides in the global cell therapy landscape
Another cell therapy rising star, RepliCel Life Sciences, is harnessing the
BlogsPosts
As Seen In
9 Challenges Keeping Cell And Gene Therapy Executives Up At Night
Despite recent progress in regenerative medicine, cell and gene therapy executives
BlogsPosts
Press Release
RepliCel Life Sciences Announces Signed Licensing and Co-Development Deal for Greater China
Skin rejuvenation and tendon regeneration products to be commercialized in Greater China in partnership with
BlogsPosts
As Seen In
Is the Age-Old Quest for a Baldness Cure Reaching Its End?
Click here to read the full article and interview as it appears
BlogsPosts
As Seen In
RepliCel's regenerative technology could take the "Polar Silk Road" to China
New opportunities are arising at every turn for the regenerative medicine
BlogsPosts
Press Release
RepliCel Life Sciences Now Finalizing its Strategic Investment Partnership with China-based YOFOTO
A revised binding term sheet reflects improved terms and positions the parties for closing the
BlogsPosts
As Seen In
Regenerative Medicine Company's China Deal is 'Dramatically Transformational'
Echelon Wealth Partners detailed the terms and impact of this cell therapy developer's recent alliance
BlogsPosts
Press Release
RepliCel CEO Provides 2018 Shareholder Update
With a new Asian partnership and 2017 deliverables met, RepliCel is primed and ready for
BlogsPosts
Press Release
RepliCel Life Sciences Lands Commitment for Key Investment Partnership
YOFOTO (China) Health Industry Co. Ltd to Invest in Becoming RepliCel's Strategic Partner for Greater
BlogsPosts
As Seen In
From stem cells to revenue: Bringing regenerative medicine to the masses
RepliCel lands Asian partnership to optimize the development of its biotech
BlogsPosts
Event
2018 EBD Biotech Showcase
RepliCel presented and conducted one-on-one partnering meetings.

DISCLAIMER:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.